Bristol Myers: tightens up target EPS range
(CercleFinance.com) - On its quarterly earnings call, Bristol Myers Squibb has raised its target range for adjusted EPS to between $7.
50 and $7.65 (from $7.35 to $7.65), even with a decline in revenues that is still expected at the lower end of its forecast range.
For Q3 2023, the pharmaceutical company reports adjusted EPS that edged up 1% to $2, on revenues that fell 2% to just under $11bn (-3% at constant exchange rates) due to lower Revlimid sales.
Management says that it remains focused on accelerating commercial performance, advancing its pipeline and leveraging financial leeway to seize business development opportunities.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
50 and $7.65 (from $7.35 to $7.65), even with a decline in revenues that is still expected at the lower end of its forecast range.
For Q3 2023, the pharmaceutical company reports adjusted EPS that edged up 1% to $2, on revenues that fell 2% to just under $11bn (-3% at constant exchange rates) due to lower Revlimid sales.
Management says that it remains focused on accelerating commercial performance, advancing its pipeline and leveraging financial leeway to seize business development opportunities.
Copyright (c) 2023 CercleFinance.com. All rights reserved.